Recombinant Human FXR Protein

Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, plays a critical role in regulating bile acid metabolism, lipid homeostasis, and glucose metabolism, positioning it as a promising target for therapeutic interventions in metabolic diseases. FXR is primarily expressed in the liver and intestines, where it governs the transcription of genes involved in bile acid synthesis and transport, thus maintaining bile acid homeostasis. The importance of FXR in disease contexts, such as non-alcoholic fatty liver disease (NAFLD) and cholestasis, has sparked increased interest in its regulatory mechanisms. Recent research has focused on the design and synthesis of FXR recombinant proteins to elucidate its structural and functional properties. These recombinant FXR proteins are employed in various assays to study ligand binding, gene transcriptional regulation, and protein-protein interactions, providing valuable insights into the receptor's physiological roles. Additionally, the development of FXR agonists is being explored as a potential therapeutic strategy to combat metabolic disorders, highlighting the necessity for a deeper understanding of FXR’s mechanisms via recombinant technology. Overall, studying FXR recombinant proteins facilitates advancements in the search for novel interventions against metabolic and liver-related diseases.